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A CROSS-OVER RANDOMISED CONTROLLED
TRIAL TO COMPARE PSYCHOLOGICAL
BARRIERS TO INSULIN SELF-INJECTION WITH
THE INNOLET AND VIAL/SYRINGE
Skovlund SE1, Lyness WH2, Nicklasson L2
1Novo Nordisk, Sorgenfri, Denmark; 2Novo Nordisk
Pharmaceuticals, Princeton, NJ, USA
OBJECTIVES: The timely initiation of insulin therapy in
patients with type-2 diabetes who fail to achieve good
control on oral antidiabetic therapy is pivotal to success-
ful health outcomes in diabetes. Yet, signiﬁcant barriers
exist to patient acceptance of insulin therapy and to ade-
quate self-management of insulin regimens once initiated.
The disposable insulin device, InnoLet, is designed to
meet the needs of elderly patients. This study set out 
to evaluate the differences in psychological fear of self-
injecting insulin and perception of barriers to compliance
with the insulin regimen in patients using the InnoLet pre-
ﬁlled device and the vial and syringe. METHODS: Eighty
diabetes patients >60 years of age and having visual and
or motor disabilities were enrolled in this two-period
crossover study, which had as primary aim to evaluate
resource utilisation and patient preference. Subjects had
difﬁculty or required caregiver assistance for their previ-
ous regimen of injections by vial/syringe. Subjects were
randomised to use of either vial and syringe or InnoLet
for 6 weeks, and then assigned the opposite treatment for
six weeks. At baseline and at the end of each period, 
subjects completed the Diabetes Fear of Self-injection
Questionnaire (D-FISQ) and questions about barriers to
insulin self-care, treatment satisfaction and preference.
RESULTS: The D-FISQ showed good internal consis-
tency. Compared to baseline values, InnoLet treatment
resulted in an improvement of 39% and 67% respectively
in each of the 2 groups in fear of self-injection, whereas
vial-syringe treatment resulted in small improvements 
of 4,7% and 17% respectively from baseline. Detailed
statistical analyses of the relationships between injection
fear, treatment barriers and health care utilisation further
demonstrate the clinical importance of injection fear.
CONCLUSION: The preﬁlled InnoLet device offers
important psychological beneﬁts to elderly insulin depen-
dent diabetes patients with visual and or motor dis-
abilities. The clinical signiﬁcance of these ﬁndings is
substantial, given the signiﬁcant health gains that can be
obtained with effective insulin therapy.
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TYPE 1 DIABETES, LONG-TERM
COMPLICATIONS AND QUALITY OF LIFE
MEASURED WITH RAND-36 HEALTH PROFILE
MEASURE
Hahl J1, Hämäläinen H2, Simell T3, Simell O3
1Turku School of Economics and Business Administration,
Turku, Finland; 2Social Insurance Institution,Turku, Finland;
3University of Turku,Turku, Finland
OBJECTIVES: Proﬁle measures of health-related quality
of life (HRQoL) are not adequate for all purposes in
health economics, but when the effects of a disease or
medical treatment to some speciﬁc domain of health are
considered, proﬁle measures can provide results that are
illustrative and easy to interpret. In this study we examine
how the effects of type 1 diabetes (TID) and the symp-
toms of its chronic long-term complications affect the
hypothesized physical and mental domains of HRQoL.
METHODS: A representative sample of patients with
TID was selected randomly from the Finnish drug reim-
bursement registry. Patients then reported symptoms,
diagnoses, and treatments indicating time of appearance
and presence of long-term complications, and ﬁlled
RAND-36 questionnaire. An explorative factor analysis
was performed to test the hypothesis of 2-factor model
of health. The results were validated with split-sample
analysis. Regression analyses were used in estimating the
effects of age, gender and symptoms of long-term com-
plications to the factor component T-scores. RESULTS:
Of the 752 (70.8%) patients who responded, 592 were
with TID and 96.2% completed the RAND-36 question-
naire. Factor analysis of our data supports the theory of
the 2-factor model of health; physical and mental health
components were reﬂected unambiguously by different
RAND-36 dimensions. The regression results show that
the symptoms of long-term complications inﬂuence much
stronger on physical than mental domain of the HRQoL.
The number of signiﬁcant symptoms was higher in phys-
ical component model (5/8 vs. 3/8) and the coefﬁcient
values of those were higher (3.1–4.4 vs. 2.3–3.7). CON-
CLUSIONS: TID and especially the symptoms of its long-
term complications affect mainly the physical domain of
health, although the mental domain is also affected. The
prevalence of long-term complications of TID in different
age groups is sufﬁciently high to substantially inﬂuence
on the quality of life of the patients.
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SELF-ASSESSMENT OF DIABETES CONTROL:
ACCURACY OF PATIENTS’ PERCEPTIONS
Bolge SC, McDonnell DD,Annunziata K, Eschmann B,
Donohue JA
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To determine the accuracy of self-reported
glucose levels among people with diabetes. METHODS:
In August 1999, 903 people with diabetes were sent an
at-home HbA1c test kit and a brief questionnaire about
blood glucose monitoring and diabetes management. The
sample was obtained through an on-going, longitudinal
diabetes study. A total of 450 respondents provided a self-
reported range of blood glucose levels and completed the
home test kit. The midpoint and highest glucose level
were compared to laboratory HbA1c values using a
regression equation calculated from a previously pub-
lished formula. The percentage of respondents misesti-
mating their diabetes control was determined. RESULTS:
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When evaluating the midpoint of self-reported glucose,
there is a positive correlation between respondents’ per-
ceptions and the objective measures of their diabetes
control (r = 0.434, p < 0.001). However, based on their
midpoint values, most of the patients (92%) overesti-
mated their level of control. Self-reported values for about
two-thirds of respondents (62%) differed from laboratory
results by a clinically relevant amount of more than 25%.
When evaluating respondents’ highest reported blood
glucose values rather than the midpoint of their range,
there was a slightly higher correlation, (r = 0.467, 
p < 0.001). More importantly, based on this comparison,
fewer respondents (69%) overestimated their level of
control. Only about one-third of respondents (36%) mis-
reported their glucose by more than 25%. CONCLU-
SION: Objective measures of diabetes control correlate
best with highest self-reported glucose. These ﬁndings
underscore the importance of obtaining frequent objec-
tive measures of average glucose control, and the need to
monitor glucose values at times of day when they might
be highest, rather than lowest. When it is necessary to
utilize self-reported data, researchers should realize that
the maximum of a self-reported range may most accu-
rately reﬂect true blood glucose levels.
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REAL WORLD ADHERENCE BENEFITS FROM
COMBINATION PRODUCTS UTILIZED IN
DIABETICS: SULFONYLUREAS & METFORMIN
Schaffer M, Mansukani S
Health Partners, Inc, Philadelphia, PA, USA
OBJECTIVES: To determine if medication adherence
differs when a combination sulfonylurea/metformin is uti-
lized versus each component separately. METHODS:
Diabetes mellitus (DM) is a chronic and progressive dis-
order that leads to signiﬁcant morbidity and mortality
and imposes a large economic burden on the health care
expenditures in the United States. Although there have
been major improvements and modiﬁcations in the diag-
nosis and treatment strategies of diabetes, it estimated
that one-third of patients suffering from diabetes are
undiagnosed, and hence untreated. The prevalence of dia-
betes has risen along with disease related complications
nationwide. Therefore, we decided to evaluate patient
care by analyzing Health Partners’ pharmacy and medical
claims databases for a period of 12 months to determine
our own standard of care by evaluating in-house data on
HbA1c and lipid proﬁles and compare it with the stan-
dards set forth by the NCQA required HEDIS measures.
A computer database search of pharmacy claims identi-
ﬁed diabetic patients taking oral diabetic agents, insulin
or a combination therapy from January 2001–December
2001 according to the Universal System Classiﬁcation
(USC) codes indicative of diabetic agents. Patients were
eligible for inclusion if in a 12-month period, they
received mono-therapy on Glucovance, or combination
therapy of sulfonylureas and metformin for at least three
months during the year. Adherence was deﬁned as having
received medication for a minimum of 80% of the
therapy’s duration. Lab claims for HbA1C values on these
members were collected as well. Results indicated that
members on Glucovance (n = 562) were more adherent
to therapy (55% vs 52%) than those on combination
therapy (n = 932). In terms of HbA1C control, 18.9% of
members adherent to Glucovance therapy had a HbA1C
value of <6.5mg/dl versus 16.6% of those adherent with
combination therapy. We hope to further explore these
initial ﬁndings.
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MEDICAID MANAGED CARE QUALITY AMONG
BLACK AND WHITE ADULTS WITH DIABETES
MELLITUS
Mayberry RM
Morehouse School of Medicine, Atlanta, GA, USA
OBJECTIVE: This study used Georgia Medicaid claims
data to evaluate the quality of care among African Amer-
ican (Black) and Caucasian American (White) adults with
diabetes mellitus who are enrolled in the mandatory
Georgia Better Health Care (GBHC) primary care case
management program, a managed care delivery model.
METHODS: This cohort study evaluated the quality of
care in relationship to the risk (i.e. rate) of diabetes-
related complications and hospitalization using Georgia
Medicaid eligibility and provider claim data for the
period 1996–1998 (by Chi square and multivariate 
logistic regression statistics). Black and White Medicaid
beneﬁciaries with newly diagnosed diabetes in 1996 and
1997 were followed for a 12-month period since diabetes
diagnosis through year 1997 and year 1998, respectively,
according to claim histories. Diabetes diagnoses are based
on physician-reported news claims of type-2 diabetes
(ICD-9-CM codes 250.0–250.9). Quality of care was
based on adherence to American Diabetes Association
(ADA) recommendations. RESULTS: The results of this
investigation indicated poor adherence to ADA recom-
mendations. Among the 3514 Medicaid beneﬁciaries with
diabetes who were enrolled for the entire 12-month
period after the initial diagnosis, only 22%, 11%, 15%,
and 2% received the ADA annually recommended HbA1c
test, eye exam, lipid proﬁle, or any nephropathy tests,
respectively. Although similarly likely to receive HbA1c
and nephropathy tests, Blacks were less likely to receive
eye exams (p = 0.0347) and lipid proﬁles (p < 0.0001),
independent of such variables as age, gender, insulin
status, number of clinic visits, and health plan option. The
results also indicated that the 12-month hospitalization
rate among Black beneﬁciaries was 1.6 times higher than
the rate among White beneﬁciaries. CONCLUSIONS:
GBHC, currently the only health plan option for Medic-
aid beneﬁciaries, has not achieved quality standards or an
equitable system of care for Georgia Medicaid beneﬁcia-
ries with diabetes.
